MRG 003
Alternative Names: MRG-003Latest Information Update: 23 May 2025
At a glance
- Originator Miracogen
- Developer Lepu Biopharma; Miracogen
- Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotherapies; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Nasopharyngeal cancer; Squamous cell cancer
- Phase II Biliary cancer; Gastric cancer; Non-small cell lung cancer
- Phase I/II Solid tumours
Most Recent Events
- 16 May 2025 Shanghai Miracogen plans a phase III Magic-C002 trial for Nasopharyngeal cancer (Combination therapy, Recurrent, Metastatic disease, Second-line therapy or greater) in China (IV) in may 2025 (NCT06976190)
- 06 May 2025 Groupe Oncologie Radiotherapie Tete et Cou in collaboration with Lepu Medical Technology plans a phase II IDEAL trial for Head and Neck Squamous Cell Carcinoma (Late-stage disease, Monotheray, Combination therapy) in June 2025 (IV) (NCT06959108 )
- 31 Jul 2024 Lepu Biopharma plans a phase II trial in Squamous cell cancer (Neoadjuvant therapy, Late-stage disease, First-line therapy, Combination therapy) (IV) in August 2024 (NCT06530914)